ProBio试验:分子生物标志物推进转移性去势抵抗性前列腺癌的个体化治疗决策
ProBio是一项多中心、结局自适应、多臂、生物标志物驱动的平台试验,旨在为转移性去势抵抗性前列腺癌(mCRPC)男性定制治疗决策。试验通过靶向测序循环肿瘤与胚系DNA确定生物标志物特征,将患者分层后随机分配至当前临床实践(对照)或基于分子特征的择治。结局自适应随机化可早期识别有前景的治疗,当某生物标志物-治疗组合相比对照显示改善无进展生存期(PFS)的概率达85%时,该组合从平台毕业并进入无缝确证性试验。
要点
- ProBio是生物标志物驱动的mCRPC平台试验,采用结局自适应随机化。
- 生物标志物特征通过循环肿瘤与胚系DNA靶向测序确定。
- 生物标志物-治疗组合改善PFS概率达85%时从平台毕业进入确证试验。
核心结论
- ProBio设计可使有前景的治疗-生物标志物组合快速从平台毕业并获确证,以加速临床转化。
研究设计与样本
- 多中心、结局自适应、多臂、生物标志物驱动的平台试验,针对mCRPC男性。
- 患者基于测序结果分层,随机分配至当前临床实践(对照)或分子驱动的治疗选择。
主要发现
- 多种mCRPC疗法对PFS改善有限,可能由肿瘤分子异质性解释。
- 已识别若干预后分子生物标志物,可能具有指导治疗选择并延长PFS的预测潜力。
关键数值与推荐
- 生物标志物-治疗组合相比对照改善PFS的概率达85%时从平台毕业。
- 毕业组合进入无缝确证性试验,采用固定随机化进一步评估。
临床怎么用
- 基于循环肿瘤与胚系DNA靶向测序的生物标志物特征指导mCRPC治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogeneity. Several prognostic molecular biomarkers have been identified for mCRPC that may have predictive potential to guide treatment selection and prolong PFS. We designed a platform trial to test this hypothesis. METHODS: The Prostate-Biomarker (ProBio) study is a multi-center, outcome-adaptive, multi-arm, biomarker-driven platform trial for tailoring treatment decisions for men with mCRPC. Treatment decisions in the experimental arms are based on biomarker signatures defined as mutations in certain genes/pathways suggested in the scientific literature to be important for treatment response in mCRPC. The biomarker signatures are determined by targeted sequencing of circulating tumor and germline DNA using a panel specifically designed for mCRPC. DISCUSSION: Patients are stratified based on the sequencing results and randomized to either current clinical practice (control), where the treating physician decides treatment, or to molecularly driven treatment selection based on the biomarker profile. Outcome-adaptive randomization is implemented to early identify promising treatments for a biomarker signature. Biomarker signature-treatment combinations graduate from the platform when they demonstrate 85% probability of improving PFS compared to the control arm. Graduated combinations are further evaluated in a seamless confirmatory trial with fixed randomization. The platform design allows for new drugs and biomarkers to be introduced in the study. CONCLUSIONS: The ProBio design allows promising treatment-biomarker combinations to quickly graduate from the platform and be confirmed for rapid implementation in clinical care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03903835. Date of registration: April 4, 2019. Status: Recruiting.
引用
- Crippa A, De Laere B, Discacciati A, et al. The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials. 2020. PMID: 32586393. doi:10.1186/s13063-020-04515-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。